RTB lectin-mediated delivery of lysosomal α-L-iduronidase mitigates disease manifestations systemically including the central nervous system

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Mucopolysaccharidosis type I (MPS I) is a lysosomal disease resulting from deficiency in the α-L-iduronidase (IDUA) hydrolase and subsequent accumulation of glycosaminoglycan (GAG). Clinically, enzyme replacement therapy (ERT) with IDUA achieves negligible neurological benefits presumably due to blood-brain-barrier (BBB) limitations. To investigate the plant lectin ricin B chain (RTB) as a novel carrier for enzyme delivery to the brain, an IDUA:RTB fusion protein (IDUAL), produced in N. benthamiana leaves, was tested in a murine model of Hurler syndrome (MPS I). Affect mice (n = 3 for each group) were intravenously injected with a single dose of IDUAL (0.58, 2 or 5.8 mg IDUA equivalents/kg) and analyzed after 24 h. IDUA activities in liver, kidney and spleen increased significantly, and liver GAG levels were significantly reduced in all three groups. Plasma IDUA levels for all treated groups were high at 1 h after injection and decreased by 95% at 4 h, indicating efficient distribution into tissues. For long-term evaluations, IDUAL (0.58 or 2 mg/kg, 8 weekly injections) was intravenously injected into MPS I mice (n = 12 for each group). Thirteen days after the 8th injection, significant IDUA activity was detected in the liver and spleen. GAG levels in tissues including the brain cortex and cerebellum were significantly reduced in treated animals. Treated MPS I mice also showed significant improvement in neurocognitive testing. ELISA results showed that while there was a significant antibody response against IDUAL and plant-derived IDUA, there was no significant antibody response to RTB. No major toxicity or adverse events were observed. Together, these results showed that infusion of IDUAL allowed for significant IDUA levels and GAG reduction in the brain and subsequent neurological benefits. This RTB-mediated delivery may have significant implications for therapeutic protein delivery impacting a broad spectrum of lysosomal, and potentially neurological diseases.

Original languageEnglish (US)
Pages (from-to)105-111
Number of pages7
JournalMolecular Genetics and Metabolism
Volume123
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Iduronidase
Neurology
Lectins
Mucopolysaccharidosis I
Central Nervous System
Glycosaminoglycans
Liver
Brain
Injections
Antibody Formation
Spleen
Plant Lectins
Tissue
Deficiency Diseases
Enzyme Replacement Therapy
Ricin
Antibodies
Hydrolases
Tissue Distribution
Enzymes

Keywords

  • CNS protein delivery
  • Enzyme replacement therapy
  • Lysosomal disease
  • RTB

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural

Cite this

@article{f503cef820e24f22b453a9de9593a4c6,
title = "RTB lectin-mediated delivery of lysosomal α-L-iduronidase mitigates disease manifestations systemically including the central nervous system",
abstract = "Mucopolysaccharidosis type I (MPS I) is a lysosomal disease resulting from deficiency in the α-L-iduronidase (IDUA) hydrolase and subsequent accumulation of glycosaminoglycan (GAG). Clinically, enzyme replacement therapy (ERT) with IDUA achieves negligible neurological benefits presumably due to blood-brain-barrier (BBB) limitations. To investigate the plant lectin ricin B chain (RTB) as a novel carrier for enzyme delivery to the brain, an IDUA:RTB fusion protein (IDUAL), produced in N. benthamiana leaves, was tested in a murine model of Hurler syndrome (MPS I). Affect mice (n = 3 for each group) were intravenously injected with a single dose of IDUAL (0.58, 2 or 5.8 mg IDUA equivalents/kg) and analyzed after 24 h. IDUA activities in liver, kidney and spleen increased significantly, and liver GAG levels were significantly reduced in all three groups. Plasma IDUA levels for all treated groups were high at 1 h after injection and decreased by 95{\%} at 4 h, indicating efficient distribution into tissues. For long-term evaluations, IDUAL (0.58 or 2 mg/kg, 8 weekly injections) was intravenously injected into MPS I mice (n = 12 for each group). Thirteen days after the 8th injection, significant IDUA activity was detected in the liver and spleen. GAG levels in tissues including the brain cortex and cerebellum were significantly reduced in treated animals. Treated MPS I mice also showed significant improvement in neurocognitive testing. ELISA results showed that while there was a significant antibody response against IDUAL and plant-derived IDUA, there was no significant antibody response to RTB. No major toxicity or adverse events were observed. Together, these results showed that infusion of IDUAL allowed for significant IDUA levels and GAG reduction in the brain and subsequent neurological benefits. This RTB-mediated delivery may have significant implications for therapeutic protein delivery impacting a broad spectrum of lysosomal, and potentially neurological diseases.",
keywords = "CNS protein delivery, Enzyme replacement therapy, Lysosomal disease, RTB",
author = "Li Ou and Przybilla, {Michael J.} and Brenda Koniar and Whitley, {Chester B.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.ymgme.2017.11.013",
language = "English (US)",
volume = "123",
pages = "105--111",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - RTB lectin-mediated delivery of lysosomal α-L-iduronidase mitigates disease manifestations systemically including the central nervous system

AU - Ou, Li

AU - Przybilla, Michael J.

AU - Koniar, Brenda

AU - Whitley, Chester B.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Mucopolysaccharidosis type I (MPS I) is a lysosomal disease resulting from deficiency in the α-L-iduronidase (IDUA) hydrolase and subsequent accumulation of glycosaminoglycan (GAG). Clinically, enzyme replacement therapy (ERT) with IDUA achieves negligible neurological benefits presumably due to blood-brain-barrier (BBB) limitations. To investigate the plant lectin ricin B chain (RTB) as a novel carrier for enzyme delivery to the brain, an IDUA:RTB fusion protein (IDUAL), produced in N. benthamiana leaves, was tested in a murine model of Hurler syndrome (MPS I). Affect mice (n = 3 for each group) were intravenously injected with a single dose of IDUAL (0.58, 2 or 5.8 mg IDUA equivalents/kg) and analyzed after 24 h. IDUA activities in liver, kidney and spleen increased significantly, and liver GAG levels were significantly reduced in all three groups. Plasma IDUA levels for all treated groups were high at 1 h after injection and decreased by 95% at 4 h, indicating efficient distribution into tissues. For long-term evaluations, IDUAL (0.58 or 2 mg/kg, 8 weekly injections) was intravenously injected into MPS I mice (n = 12 for each group). Thirteen days after the 8th injection, significant IDUA activity was detected in the liver and spleen. GAG levels in tissues including the brain cortex and cerebellum were significantly reduced in treated animals. Treated MPS I mice also showed significant improvement in neurocognitive testing. ELISA results showed that while there was a significant antibody response against IDUAL and plant-derived IDUA, there was no significant antibody response to RTB. No major toxicity or adverse events were observed. Together, these results showed that infusion of IDUAL allowed for significant IDUA levels and GAG reduction in the brain and subsequent neurological benefits. This RTB-mediated delivery may have significant implications for therapeutic protein delivery impacting a broad spectrum of lysosomal, and potentially neurological diseases.

AB - Mucopolysaccharidosis type I (MPS I) is a lysosomal disease resulting from deficiency in the α-L-iduronidase (IDUA) hydrolase and subsequent accumulation of glycosaminoglycan (GAG). Clinically, enzyme replacement therapy (ERT) with IDUA achieves negligible neurological benefits presumably due to blood-brain-barrier (BBB) limitations. To investigate the plant lectin ricin B chain (RTB) as a novel carrier for enzyme delivery to the brain, an IDUA:RTB fusion protein (IDUAL), produced in N. benthamiana leaves, was tested in a murine model of Hurler syndrome (MPS I). Affect mice (n = 3 for each group) were intravenously injected with a single dose of IDUAL (0.58, 2 or 5.8 mg IDUA equivalents/kg) and analyzed after 24 h. IDUA activities in liver, kidney and spleen increased significantly, and liver GAG levels were significantly reduced in all three groups. Plasma IDUA levels for all treated groups were high at 1 h after injection and decreased by 95% at 4 h, indicating efficient distribution into tissues. For long-term evaluations, IDUAL (0.58 or 2 mg/kg, 8 weekly injections) was intravenously injected into MPS I mice (n = 12 for each group). Thirteen days after the 8th injection, significant IDUA activity was detected in the liver and spleen. GAG levels in tissues including the brain cortex and cerebellum were significantly reduced in treated animals. Treated MPS I mice also showed significant improvement in neurocognitive testing. ELISA results showed that while there was a significant antibody response against IDUAL and plant-derived IDUA, there was no significant antibody response to RTB. No major toxicity or adverse events were observed. Together, these results showed that infusion of IDUAL allowed for significant IDUA levels and GAG reduction in the brain and subsequent neurological benefits. This RTB-mediated delivery may have significant implications for therapeutic protein delivery impacting a broad spectrum of lysosomal, and potentially neurological diseases.

KW - CNS protein delivery

KW - Enzyme replacement therapy

KW - Lysosomal disease

KW - RTB

UR - http://www.scopus.com/inward/record.url?scp=85035334874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035334874&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2017.11.013

DO - 10.1016/j.ymgme.2017.11.013

M3 - Article

C2 - 29198892

AN - SCOPUS:85035334874

VL - 123

SP - 105

EP - 111

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 2

ER -